Century Therapeutics (IPSC)
(Delayed Data from NSDQ)
$3.03 USD
+0.03 (1.00%)
Updated May 3, 2024 04:00 PM ET
After-Market: $3.06 +0.03 (0.99%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Century Therapeutics, Inc. (IPSC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$14.83 | $24.00 | $9.00 | 394.33% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Century Therapeutics, Inc. comes to $14.83. The forecasts range from a low of $9.00 to a high of $24.00. The average price target represents an increase of 394.33% from the last closing price of $3.00.
Analyst Price Targets (6 )
Broker Rating
Century Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.29 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, six are Strong Buy, representing 85.71% of all recommendations. A month ago, Strong Buy represented 85.71%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.29 | 1.29 | 1.29 | 1.29 | 1.29 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/15/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
3/15/2024 | Canaccord Genuity | William Maughan | Strong Buy | Strong Buy |
3/1/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Strong Buy | Strong Buy |
3/1/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
3/1/2024 | William Blair | Sami Corwin | Hold | Hold |
10/2/2023 | Guggenheim Securities | Kelsey Goodwin | Strong Buy | Strong Buy |
9/28/2023 | SVB Securities | Daina M Graybosch | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.29 |
ABR (Last week) | 1.29 |
# of Recs in ABR | 7 |
Average Target Price | $14.83 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 98 of 252 |
Current Quarter EPS Est: | -0.50 |